• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Leuna Biorefinery Opening Could Be A Big Moment For UPM Stock

    Simply Wall St·10/18/2026 19:26:45
    Listen to the news
    • UPM-Kymmene Oyj has started operations at its €1,370 million Leuna biorefinery in Germany, converting sustainably sourced wood and sawmill residues into 220,000 tonnes of renewable biochemicals per year for use in products such as clothing, packaging, cosmetics, building materials and tires.
    • The Leuna site uses enzymatic hydrolysis to turn low value beechwood thinnings and local sawmill residues into industrial sugars and lignin, creating a new revenue platform in renewable chemicals that is operationally ramping with stable production of lignin based specialty products.
    • We will now examine how UPM-Kymmene Oyj's investment narrative relates to the Leuna biorefinery's scale and biochemical ramp up progress.
    Spot opportunities beyond UPM-Kymmene Oyj by screening for peers with similar long-term transition themes using our curated 234 resilient stocks with low risk scores.

    UPM-Kymmene Oyj Investment Narrative Recap

    To own UPM-Kymmene Oyj, you need to buy into a shift from legacy graphic paper toward biofuels, energy and wood based biochemicals, while the balance sheet carries the weight of that transition. The Leuna biorefinery moving into stable operation on key lines supports that story, but it also keeps capital intensity and start up losses in clear view.

    The near term hinge remains how quickly Leuna cash burn tapers versus earnings from Biofuels, Energy and Fibres South. The biggest risk is that higher depreciation, operating costs and tight free cash flow from Leuna and working capital keep leverage elevated and limit financial flexibility.

    The most relevant recent development for that thesis is the Leuna biorefinery inauguration and reported progress on enzymatic hydrolysis and lignin based specialty products. You now have confirmation that this €1.37b asset is producing at industrial scale, with sales of new biochemicals ramping, rather than sitting idle on the balance sheet.

    For catalysts, this matters because Leuna is intended to become a new revenue stream in renewable chemicals. At the same time, the proposed graphic paper joint venture with Sappi targets exposure reduction to a structurally declining segment. Execution risk is clear. If biochemicals losses and working capital needs stay heavy, they could dilute the benefits from more profitable units.

    What The Current Forecasts Assume For UPM-Kymmene Oyj

    Analysts are effectively tying UPM-Kymmene Oyj's Leuna progress into a broader set of expectations that run out to 2029. The current analyst framework assumes revenue grows by 2.0% a year over the next three years and that profit margins move from 6.6% today to 11.1% by that point. On earnings, the consensus view is that profit reaches €1.1b by about 2029, compared with €624.0m today, with a wide spread between bullish and cautious views around that midpoint. These projections rely on the share count staying broadly steady and on investors being willing to pay about 14.6x P/E on those future earnings, compared with 21.1x today.

    UPM-Kymmene Oyj's narrative projects €10.1b revenue and €1.1b earnings by 2029. This rests on 2.0% yearly revenue growth and an earnings increase of about €476m from €624.0m today.

    On valuation, the same analyst set links those operating assumptions to a consensus price target of €25.57 per share. That is only 2.3% above the current €24.97 price, which indicates that the average view already bakes in a fair amount of value from bio-based projects like Leuna. To align with that target, you would need to be comfortable that the group can deliver the projected €10.1b of sales and €1.1b of profit in 2029 at a 14.6x P/E, discounted at roughly 6.9%.

    Uncover why UPM-Kymmene Oyj's fair value is essentially aligned with its current price.

    HLSE:UPM 1-Year Stock Price Chart
    HLSE:UPM 1-Year Stock Price Chart

    Exploring Other Perspectives

    You are not alone if you see the Leuna start up and think there could be a bigger upside for UPM Kymmene Oyj than the baseline. The most optimistic analysts were already pencilling in about €10.9b of revenue and €1.4b of earnings by 2029 before this update, so they are assuming that Leuna reaches strong EBIT faster. Opinions differ widely, so treat today’s news as a trigger to compare several viewpoints, not to default to any single interpretation.

    Explore 2 other UPM-Kymmene Oyj fair value estimates, including one that suggests the potential for as much as 76% upside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond UPM-Kymmene Oyj?

    Once you have formed a view on UPM-Kymmene Oyj, it often helps to compare that thesis with other opportunities that have different risk and income profiles. The Simply Wall St Screener can help you quickly filter for stocks that match the type of balance sheet strength, valuation profile or income stream you want to focus on next.

    • If capital preservation sits high on your list, start with a focus on resilient businesses and check out the 234 resilient stocks with low risk scores that filter well on Simply Wall St's risk scoring.
    • If income is a key part of your plan, use the tool to focus on higher yielding payers through the 215 dividend fortresses that meet your dividend criteria.
    • If you want to look at less widely followed opportunities, widen your research using the 614 high quality undiscovered gems and see which quieter stories line up with your own framework.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.